New CAR-T therapy aims to wipe out hidden lymphoma cells before they return
NCT ID NCT07443137
First seen Mar 09, 2026 · Last updated May 07, 2026 · Updated 4 times
Summary
This early-phase trial tests a personalized cell therapy called rapcabtagene autoleucel (YTB323) in 20 adults with large B-cell lymphoma who still have tiny amounts of cancer detectable after their first standard treatment. The goal is to see if the therapy can turn those leftover cancer signals negative, potentially lowering the risk of relapse. Participants must have high-risk disease and positive minimal residual disease (MRD) to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.